U.S. FDA Approves Akeega (niraparib And Abiraterone Acetate) Dual Action Tablet For Treatment Of Patients With BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has approved Akeega, a dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer. The drug is a combination of niraparib and abiraterone acetate.
August 11, 2023 | 8:19 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
The approval of Akeega by the FDA could potentially impact the stock of Johnson & Johnson (JNJ), if they are involved in its production or distribution.
The news does not provide specific details about Johnson & Johnson's involvement with Akeega. Therefore, the potential impact on JNJ's stock is uncertain at this time.
CONFIDENCE 50
IMPORTANCE 50
RELEVANCE 50